Seeking Alpha

Sangamo BioSciences announces evidence of HIV functional control with SB-728-T

  • Sangamo BioSciences (SGMO) presents what it says is "the first evidence that sustained functional control of HIV in the absence of antiretroviral therapy is possible."
  • The company says viral load became undetectable during an ART treatment interruption in three of seven patients treated with SB-728-T.
  • In one patient, viral load has been undetectable for seven weeks.
  • The company calls this "a major step toward immunological functional control of HIV." (PR)
  • SGMO +3.2% AH
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector